CNS Anticancer Drug Discovery and Development Conference White Paper

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma

(2015) A. L. Di Stefano et al.   CLINICAL CANCER RESEARCH

Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood-brain barrier

(2015) KE Parrish et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research

(2015) Donald A. Berry   Molecular Oncology

Translating slow-binding inhibition kinetics into cellular and in vivo effects

(2015) Grant K Walkup et al.   Nature Chemical Biology

Molecular Pathways: Regulation and Targeting of Kinetochore-Microtubule Attachment in Cancer

(2014) J. A. Herman et al.   CLINICAL CANCER RESEARCH

BuGZ Is Required for Bub3 Stability, Bub1 Kinetochore Function, and Chromosome Alignment

(2014) Chad M. Toledo et al.   DEVELOPMENTAL CELL

Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models

(2014) X. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

ANG4043, a Novel Brain-Penetrant Peptide-mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice

(2014) A. Regina et al.   MOLECULAR CANCER THERAPEUTICS

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas

(2014) N. Sabha et al.   NEURO-ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumoral Modeling of Gefitinib Pharmacokinetics and Pharmacodynamics in an Orthotopic Mouse Model of Glioblastoma

(2013) J. Sharma et al.   CANCER RESEARCH

The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement

(2013) L. C. Villaruz et al.   CLINICAL CANCER RESEARCH

Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A

(2013) C. G. Hubert et al.   GENES & DEVELOPMENT

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients

(2013) Marzena Anna Lewandowska et al.   Molecular Diagnosis & Therapy

The integrated landscape of driver genomic alterations in glioblastoma

(2013) Veronique Frattini et al.   NATURE GENETICS

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

(2013) A. D. Norden et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

(2013) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study

(2013) D. H. Pafundi et al.   NEURO-ONCOLOGY

Engineering Agatoxin, a Cystine-Knot Peptide from Spider Venom, as a Molecular Probe for In Vivo Tumor Imaging

(2013) Sarah J. Moore et al.   PLoS One

Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma

(2013) Sarah J. Moore et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Proteomics and Transcriptomics Investigation of the Venom from the Barychelid Spider Trittame loki (Brush-Foot Trapdoor)

(2013) Eivind Undheim et al.   Toxins

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

(2012) Marcel Kool et al.   ACTA NEUROPATHOLOGICA

Noninvasive Determination of 2-[18F]-Fluoroisonicotinic Acid Hydrazide Pharmacokinetics by Positron Emission Tomography in Mycobacterium tuberculosis-Infected Mice

(2012) E. A. Weinstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Targeting the PI3K Pathway in the Brain--Efficacy of a PI3K Inhibitor Optimized to Cross the Blood-Brain Barrier

(2012) L. Salphati et al.   CLINICAL CANCER RESEARCH

In Vivo Bio-imaging Using Chlorotoxin-based Conjugates

(2012) Mark R. Stroud et al.   CURRENT PHARMACEUTICAL DESIGN

Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up

(2012) Sagar Agarwal et al.   CURRENT PHARMACEUTICAL DESIGN

Molecular subgroups of medulloblastoma

(2012) Paul A Northcott et al.   Expert Review of Neurotherapeutics

Analytical Approach to Characterize the Intratumoral Pharmacokinetics and Pharmacodynamics of Gefitinib in a Glioblastoma Model

(2012) Jyoti Sharma et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents

(2012) S. Agarwal et al.   MOLECULAR CANCER THERAPEUTICS

Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

(2012) Arvin C. Dar et al.   NATURE

Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines

(2012) Colin Correnti et al.   PLoS One

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

(2012) D. Singh et al.   SCIENCE

Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers

(2012) Krister J. Barkovich et al.   Cancer Discovery

Cancer-Specific Requirement for BUB1B/BUBR1 in Human Brain Tumor Isolates and Genetically Transformed Cells

(2012) Yu Ding et al.   Cancer Discovery

Molecular subgroups of medulloblastoma: the current consensus

(2011) Michael D. Taylor et al.   ACTA NEUROPATHOLOGICA

Drosophilacancer models

(2011) Vivek A. Rudrapatna et al.   DEVELOPMENTAL DYNAMICS

Modeling tumor invasion and metastasis in Drosophila

(2011) W. O. Miles et al.   Disease Models & Mechanisms

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

(2011) Sagar Agarwal et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Drosophila melanogaster as a model system for human brain cancers

(2011) Renee D. Read   GLIA

New Mode of Action for a Knottin Protein Bioinsecticide

(2011) Christophe Chouabe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors

(2011) Yasuo Uchida et al.   JOURNAL OF NEUROCHEMISTRY

Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy

(2011) L. Liu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

(2011) MJ van den Bent et al.   LANCET ONCOLOGY

The resurgence of covalent drugs

(2011) Juswinder Singh et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical trial end points for high-grade glioma: the evolving landscape

(2011) D. A. Reardon et al.   NEURO-ONCOLOGY

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

(2011) P. Y. Wen et al.   NEURO-ONCOLOGY

Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas

(2011) Michael A. Vogelbaum et al.   NEUROSURGERY

Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors

(2011) Ashok D. Bandaranayake et al.   NUCLEIC ACIDS RESEARCH

Human Disease Models in Drosophila melanogaster and the Role of the Fly in Therapeutic Drug Discovery

(2011) U. B. Pandey et al.   PHARMACOLOGICAL REVIEWS

Functional Mutation of Multiple Solvent-Exposed Loops in the Ecballium elaterium Trypsin Inhibitor-II Cystine Knot Miniprotein

(2011) Richard H. Kimura et al.   PLoS One

Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

(2010) Travis T. Wager et al.   ACS Chemical Neuroscience

Drug–target residence time: critical information for lead optimization

(2010) Hao Lu et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome

(2010) Yoon-Jae Cho et al.   JOURNAL OF CLINICAL ONCOLOGY

Medulloblastoma Comprises Four Distinct Molecular Variants

(2010) Paul A. Northcott et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of passive blood–brain partitioning: Straightforward and effective classification models based on in silico derived physicochemical descriptors

(2010) Santiago Vilar et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

(2010) W. K. A. Yung et al.   NEURO-ONCOLOGY

Rapid Pharmacokinetic and Biodistribution Studies Using Cholorotoxin-Conjugated Iron Oxide Nanoparticles: A Novel Non-Radioactive Method

(2010) Michelle Jeung-Eun Lee et al.   PLoS One

Slow-Onset Inhibition of the FabI Enoyl Reductase fromFrancisella tularensis: Residence Time andin VivoActivity

(2009) Hao Lu et al.   ACS Chemical Biology

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

(2009) David A. Reardon et al.   CANCER

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Treatment of recurrent high-grade gliomas

(2009) Patrick Y Wen et al.   CURRENT OPINION IN NEUROLOGY

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

(2009) Gregor Dresemann et al.   JOURNAL OF NEURO-ONCOLOGY

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

(2009) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

The transcriptional network for mesenchymal transformation of brain tumours

(2009) Maria Stella Carro et al.   NATURE

Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity

(2009) Richard H. Kimura et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Interrogating and Predicting Tolerated Sequence Diversity in Protein Folds: Application to E. elaterium Trypsin Inhibitor-II Cystine-Knot Miniprotein

(2009) Jennifer L. Lahti et al.   PLoS Computational Biology

A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients

(2008) L. Rosso et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

(2008) Eric Raymond et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

(2008) Marta Santisteban et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

(2008) J. F. de Groot et al.   JOURNAL OF NEURO-ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features

(2008) Marcel Kool et al.   PLoS One